President Trump Cleaning Up Biden's Marijuana Mess - MMJ Preparing to Move FDA Huntington's Cannabis Trials Forward
Trump Prepares to Clean Up Biden's "Do-Nothing" Marijuana Mess: Why MMJ International Holdings Takes the Lead in a Pharmaceutical Cannabis Reset.
Dispensaries sell products. MMJ builds medicine. And as the country re-learns the difference, MMJ takes the lead.
WASHINGTON, December 16, 2025 (Newswire.com) - As reports circulate that President Trump will issue an executive order directing federal agencies to finalize the long-stalled move of marijuana to Schedule III, MMJ International Holdings today framed the action not as a new policy, but as the necessary move to correct the regulatory vacuum created by Biden's administration.
The failure to complete the rescheduling process, initiated by the Biden White House in October 2022, has resulted in today's "Biden Mess": a chaotic $30+ billion gray market operating outside federal law, an expanding illicit trade, and a profound public health evidence gap for most products sold as "medicine."
Schedule III is Not Legalization-It is a Reality Check
MMJ stressed that Schedule III does not legalize state dispensaries or solve every banking issue automatically. Its real impact is far more disruptive: it signals the end of the gray market era and the beginning of a federally controlled, medicine-first framework.
Schedule III forces a reality check: it requires the product to be subject to FDA oversight, standardized dosing, and real clinical evidence-standards entirely foreign to the current retail-first model.
The Problem: While patients report real relief, the medical establishment is right to warn that most dispensary products are not standardized, not FDA-reviewed, and lack consistent clinical trial data for their claims. This contradiction is the core public health crisis the federal government must address.
MMJ: Built for the Only Pathway that Survives Federal Scrutiny
If President Trump's executive order is paired with a harder federal line against illicit grows, synthetic cannabinoids, and the gray-market networks exploiting the system, the industry will immediately split into two worlds:
World 1: State Retail / Quasi-Legal Markets | World 2: FDA/DEA Pharmaceutical Development |
Federally Unlawful (exposed to shifting DOJ priorities) | Federally Lawful (when executed correctly) |
Built around consumer commerce | Built around standardization, safety, and prescriptions |
High vulnerability to enforcement/money laundering | Compatible with a "law-and-order + public health" posture |
FDA Clinical Trial Pathway: Already holds Investigational New Drug (IND) clearances.
Orphan Drug Positioning: Holds designation for Huntington's Disease, aligning with a rare disease focus.
Pharmaceutical-Grade: Operates with DEA controlled substance compliance to produce standardized, precise soft-gel formulations.
The Start of Real Cannabinoid Medicine
President Trump's decision marks a pivotal moment. By forcing the completion of the Schedule III rulemaking, the White House will usher in an environment defined by: order, enforcement, and standardization.
In that environment, MMJ International Holdings is not simply "positioned well." MMJ is positioned uniquely-it is one of the only U.S. groups built to function in the world federal regulators actually intend to create.
Dispensaries sell products. MMJ builds medicine. And as the country re-learns the difference, MMJ takes the lead.
About MMJ International Holdings
MMJ International Holdings is a U.S. based biopharmaceutical company developing natural, plant derived cannabinoid medicines for FDA approval. Its subsidiaries-MMJ BioPharma Cultivation and MMJ BioPharma Labs-operate under federal law to advance pharmaceutical soft-gel cannabinoid formulations targeting Huntington's Disease and Multiple Sclerosis.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-85832
SOURCE: MMJ International Holdings
Source: MMJ International Holdings
Share:
Tags: biden marijuana policy failure, biopharma cannabinoid pipeline, botanical drug development, cannabinoid softgel capsules, CANNABIS, cannabis clinical trials, cannabis drug approval process, cannabis investment thesis, cannabis law enforcement, cannabis pharmaceutical pathway, cannabis regulation reform, cannabis research barriers, cannabis schedule iii impact, cartel marijuana operations, controlled substances act cannabis, DEA, dea accountability, dea cannabis delay, dea obstruction of medical research, dea rulemaking cannabis, DEAHQ, delta 8 ban, doj marijuana enforcement, drug policy reform united states, DUANE BOISE, DUANE BOISE FLORIDA, DUANE BOISE HEALTHCARE, DUANE BOISE JAMAICA, end cannabis loopholes, fda cannabinoid drug development, fda ind cannabis, federal cannabis policy, federal supremacy cannabis, federally legal cannabis, gray market cannabis, hemp thc crackdown, illicit cannabis market, MARIJUANA, marijuana enforcement priorities, marijuana federal register timeline, marijuana public comment period, marijuana rescheduling, medical cannabis evidence gap, medicine not dispensaries, mmj biopharma cultivation, mmj biopharma labs, mmj international holdings, multiple sclerosis cannabinoid therapy, orphan drug designation huntington’s disease, pharmaceutical cannabis company, pharmaceutical grade cannabis, PRESIDENT TRUMP RESCHEDULING, schedule iii marijuana, science based cannabis medicine, seven year dea delay, standardized cannabinoid medicine, state legal marijuana conflict, synthetic cannabinoids ban, TERRY COLE DEA, trump marijuana executive order
Additional Images
